SIC
BHVN

SJS Investment Consulting’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

SJS Investment Consulting’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$0 Buy
+2
New +$249 ﹤0.01% 1499

Other funds holding BHVN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SJS Investment Consulting's BHVN Position: Q1 2022 in Review

SJS Investment Consulting opened a new position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q1 2022: 2 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1499 among its holdings.

307 funds tracked by Wall St. Rank hold BHVN as of Q1 2022.

  • SJS Investment Consulting held 2 shares of Biohaven Pharmaceutical Holding Company Ltd. worth $0 as of Q1 2022.
  • Biohaven Pharmaceutical Holding Company Ltd. was a new SJS Investment Consulting position in Q1 2022.
  • Biohaven Pharmaceutical Holding Company Ltd. made up ﹤0.01% of SJS Investment Consulting's portfolio in Q1 2022, its #1499 holding.
  • 307 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q1 2022.

Based on SJS Investment Consulting's 13F filing for Q1 2022, filed 5 May 2022.